宫颈癌的精准医学
Precision medicine for cervical cancer.
作者信息
Manrriquez Erica N, Zakhour Mae, Salani Ritu
机构信息
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
出版信息
Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):1-5. doi: 10.1097/GCO.0000000000000755.
PURPOSE OF REVIEW
To summarize the data on precision medicine for cervical cancer including the use of potential biomarkers. We also review ongoing areas of research in cervical cancer therapeutics.
RECENT FINDINGS
In the current clinical practice, programmed death ligand 1 (PD-L1) expression is used to select patients with cervical cancer for treatment with checkpoint inhibitors. However, more recently presented data suggest that PD-L1 may not be a fully accurate biomarker for selection and further analysis is warranted. With the publication of the molecular landscape of cervical cancer, tumor profile-based therapy selection is of greater interest (i.e. targeting PI3K and HER2).
SUMMARY
In this review, we discuss the role of potential biomarkers for cervical cancer that may assist with the selection of precision therapies. Enrolling patients on active clinical trials will help clarify the role of targeting specific mutations.
综述目的
总结宫颈癌精准医学的数据，包括潜在生物标志物的应用。我们还回顾了宫颈癌治疗领域正在进行的研究。
最新发现
在当前临床实践中，程序性死亡配体1（PD-L1）表达用于选择宫颈癌患者接受检查点抑制剂治疗。然而，最近公布的数据表明，PD-L1可能不是用于选择的完全准确的生物标志物，有必要进行进一步分析。随着宫颈癌分子图谱的公布，基于肿瘤特征的治疗选择更受关注（即靶向PI3K和HER2）。
总结
在本综述中，我们讨论了可能有助于精准治疗选择的宫颈癌潜在生物标志物的作用。让患者参与正在进行的临床试验将有助于阐明靶向特定突变的作用。
Zotero 插件